Tempest Therapeutics 8-K Filing - Mar 23

The Big Picture

Tempest Therapeutics filed a Form 8-K on Mar 23 that flags a material definitive agreement and unregistered sales of equity securities, developments investors should review closely for potential dilution or partnership impacts. The filing is a formal SEC disclosure that may affect investor sentiment even though specific financial terms were not included in the summary notice.

If you hold or watch Tempest, this filing is a prompt to check the attached exhibits and the full 8-K text to understand any contractual obligations, financings, or equity issuances described by the company.

What's Happening

Tempest Therapeutics submitted an 8-K with three primary disclosures. The form identifies the topics but the company provided the supporting exhibits for full detail in the filing itself. Key facts from the 8-K filing include:

• Filed date: 2026-03-23, the day the company formally reported the events to the SEC.
• Accession Number: 0001193125-26-118618, the SEC index identifier for this submission.
• File size: 817 KB, indicating multiple exhibits or attached documents were included.
• CIK (filer identifier): 0001544227, confirming the filing originates from Tempest Therapeutics.
• Item 1.01: Entry into a Material Definitive Agreement, which signals a new contractual relationship the company considers material.
• Item 3.02: Unregistered Sales of Equity Securities, which indicates the company issued equity outside registered public offerings under applicable exemptions.
• Item 9.01: Financial Statements and Exhibits, confirming related exhibits and any required pro forma or supplemental statements were attached.

Each of these items matters differently. The material agreement in Item 1.01 could be a partnership, licensing deal, loan, or other obligation that changes future cash flows or operations. Item 3.02 is often used to document private placements or issuances to collaborators, and investors should check whether those sales dilute outstanding shares or change ownership stakes. Item 9.01 lists exhibits and any financial schedules that provide the underlying details investors need to assess impact.

Why It Matters For Your Portfolio

The filing is a direct signal that meaningful corporate activity is underway. For shareholders and prospective buyers, the specifics in the attached exhibits will determine whether the news is constructive or dilutive.

Who should care: growth investors tracking clinical or partnership progress, liquidity-focused investors monitoring dilution risk, and traders seeking short-term catalysts. The company did not include analyst commentary in the filing, so market interpretation will depend on the exhibits and any subsequent company statements.

Risks To Consider

• Equity Dilution: Item 3.02 shows unregistered sales of equity securities, which may increase outstanding shares and dilute existing holders unless the issuance was non-dilutive or offset by other actions.
• Obligations From Agreement: Item 1.01 indicates a material definitive agreement that could create future payment obligations, milestone requirements, or revenue-sharing terms that affect cash flow.
• Information Gaps: The summary items in the 8-K do not by themselves disclose financial terms or valuations. If exhibits lack clarity, markets may react to uncertainty rather than detail.

What To Watch Next

Review the exhibits in the 8-K to understand the contractual and equity specifics. Watch for any follow-up company press releases or filings that disclose monetary terms, share counts or implementation timelines.

• Exhibits attached to Accession No. 0001193125-26-118618, which should contain the full agreements and securities documentation.
• Subsequent SEC filings or investor communications that expand on the material agreement or disclose the purchasers and quantities related to Item 3.02.
• Any company statements clarifying how the agreement affects milestones, revenue recognition, and governance.

The Bottom Line

• Tempest Therapeutics filed an 8-K on Mar 23 disclosing a material definitive agreement and unregistered equity sales; read the exhibits to see the impact.
• The filing includes Item 1.01, Item 3.02 and Item 9.01, and uses Accession No. 0001193125-26-118618 and CIK 0001544227 for reference.
• Investors should assess dilution risk and contractual obligations by reviewing the attached exhibits rather than relying on the summary alone.
• Look for follow-up filings or official company commentary for monetary terms, purchaser identities, and any changes to share counts.
• This summary is informational; analysts and market participants will need the exhibits to draw valuation or trading conclusions.

FAQ

Q: What did the 8-K filed on Mar 23 disclose?

A: The 8-K disclosed an entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), and included financial statements and exhibits (Item 9.01). The filing uses Accession No. 0001193125-26-118618.

Q: Does the filing say how many shares were issued or the deal value?

A: The summary reported the existence of unregistered sales and a material agreement but did not include deal values or share counts in the header; those details are typically in the attached exhibits referenced in Item 9.01.

Q: What should I do as an investor after this filing?

A: Review the exhibits attached to the 8-K for terms and quantities, monitor for any subsequent filings or press releases that disclose financial details, and consider dilution and contractual obligations when updating your analysis.